Tag Archives: Alan Carr

Needham Releases a Hold Rating on Gilead Sciences (GILD)

In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed last Monday at $74.56. According to TipRanks.com, Carr is a 2-star analyst with an average return

Pliant Therapeutics (PLRX) Initiated with a Buy at Needham

Pliant Therapeutics (PLRX – Research Report) received a Buy rating and a $40.00 price target from Needham analyst Alan Carr today. The company’s shares closed last Friday at $31.72. According to TipRanks.com, Carr is a 3-star analyst with an average

Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (NASDAQ: CARA) and Protagonist Therapeutics (NASDAQ: PTGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cara Therapeutics (CARA – Research Report) and Protagonist Therapeutics (PTGX – Research Report) with bullish sentiments. Cara Therapeutics (CARA) Needham analyst Alan

Needham Gives a Buy Rating to Moderna (MRNA)

In a report released today, Alan Carr from Needham assigned a Buy rating to Moderna (MRNA – Research Report), with a price target of $94.00. The company’s shares closed last Thursday at $63.91. According to TipRanks.com, Carr is a 3-star

Gilead Sciences (GILD) Receives a Hold from Needham

Needham analyst Alan Carr maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed last Monday at $75.16. According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.4% and a

Iterum Therapeutics (ITRM) Gets a Buy Rating from Needham

In a report released today, Alan Carr from Needham assigned a Buy rating to Iterum Therapeutics (ITRM – Research Report), with a price target of $7.00. The company’s shares closed last Thursday at $3.50. According to TipRanks.com, Carr is a